Cyclopharm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Cyclopharm şirketinin toplam hissedar öz sermayesi A$47.5M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$64.1M ve A$16.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$28.89m
Eşitlik	AU$47.55m
Toplam yükümlülükler	AU$16.54m
Toplam varlıklar	AU$64.09m

Son finansal sağlık güncellemeleri

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Apr 18

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Mar 31

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Oct 17

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Jun 09

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Mar 06

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CYC 'nin kısa vadeli varlıkları ( A$47.1M ) kısa vadeli yükümlülüklerini ( A$10.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: CYC şirketinin kısa vadeli varlıkları ( A$47.1M ) uzun vadeli yükümlülüklerini ( A$5.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CYC borçsuzdur.

Borcun Azaltılması: CYC şirketinin 5 yıl önce borç/öz sermaye oranı 0.2% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CYC şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: CYC tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Cyclopharm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Recent updates

New minor risk - Market cap size

Non-Executive Director recently bought AU$51k worth of stock

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

New 90-day high: AU$3.10

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

New 90-day high: AU$2.63

Cyclopharm Limited Announces A New Research Collaboration with Mcmasters University

New 90-day high - AU$1.59

First half earnings released

Finansal Durum Analizi